The FDA and the European Medicines Agency have formed a new working group focusing on incorporating patient perspectives into drug development, evaluation and post-marketing activities.
This effort will enable patients to share their experiences and provide input on best practices. Areas of discussion will include the processes for selecting and preparing participants in the agencies’ activities, ensuring that patients are independent and representative, and reporting the impact of patient involvement.
The first meeting of the working group took place via teleconference on last week, the EMA says. The group will be jointly chaired by both agencies, and is expected to meet three to four times per year.